As Biogen INC (BIIB) Share Value Declined, Holder Clearbridge Investments LLC Has Lifted Position

June 14, 2018 - By Jimmy Baldridge

Biogen Inc. (NASDAQ:BIIB) LogoInvestors sentiment decreased to 1.07 in 2018 Q1. Its down 0.10, from 1.17 in 2017Q4. It is negative, as 69 investors sold BIIB shares while 305 reduced holdings. 92 funds opened positions while 308 raised stakes. 178.22 million shares or 1.35% less from 180.65 million shares in 2017Q4 were reported. Orbimed Advsrs Ltd holds 1.04M shares or 3.53% of its portfolio. Adell Harriman Carpenter stated it has 6,171 shares or 0% of all its holdings. South Dakota Invest Council holds 67,661 shares or 0.42% of its portfolio. Weiss Multi holds 0.08% or 9,000 shares. Clarivest Asset Llc reported 72,128 shares stake. Wg Shaheen Associates Dba Whitney reported 0.01% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Rock Springs Cap LP stated it has 0.62% in Biogen Inc. (NASDAQ:BIIB). Origin Asset Limited Liability Partnership has 85,300 shares. Profund Ltd accumulated 0.93% or 85,224 shares. Segall Bryant Hamill Limited owns 0.09% invested in Biogen Inc. (NASDAQ:BIIB) for 14,534 shares. Tnb Fincl reported 23,741 shares. Sg Americas Ltd Liability Company holds 0.06% in Biogen Inc. (NASDAQ:BIIB) or 26,945 shares. North Star Invest Mgmt reported 37 shares. Sei Invests Company stated it has 0.17% in Biogen Inc. (NASDAQ:BIIB). Boston Common Asset Lc invested in 25,546 shares or 0.82% of the stock.

Since January 9, 2018, it had 1 insider buy, and 5 selling transactions for $10.09 million activity. Another trade for 5,832 shares valued at $1.92M was sold by PANGIA ROBERT W. 1,294 Biogen Inc. (NASDAQ:BIIB) shares with value of $386,712 were sold by Sandrock Alfred.

Clearbridge Investments Llc increased its stake in Biogen Inc (BIIB) by 0.51% based on its latest 2018Q1 regulatory filing with the SEC. Clearbridge Investments Llc bought 46,608 shares as the company’s stock declined 1.31% with the market. The institutional investor held 9.19M shares of the biological products (no diagnostic substances) company at the end of 2018Q1, valued at $2.52B, up from 9.14M at the end of the previous reported quarter. Clearbridge Investments Llc who had been investing in Biogen Inc for a number of months, seems to be bullish on the $64.50B market cap company. The stock decreased 0.40% or $1.23 during the last trading session, reaching $305.68. About 1.08 million shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 13.14% since June 14, 2017 and is uptrending. It has outperformed by 0.57% the S&P500.

Clearbridge Investments Llc, which manages about $105.97B US Long portfolio, decreased its stake in Honeywell Intl Inc (NYSE:HON) by 29,756 shares to 6.02M shares, valued at $870.38M in 2018Q1, according to the filing. It also reduced its holding in Vmware Inc (NYSE:VMW) by 546,629 shares in the quarter, leaving it with 2.58 million shares, and cut its stake in Splunk Inc (NASDAQ:SPLK).

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: which released: “Short Sellers Up the Ante For Major Biotechs” on June 12, 2018, also with their article: “Biogen’s head of late-stage trials leaves for Sarepta” published on June 07, 2018, published: “Better Buy: Biogen Inc. vs. Celgene” on June 03, 2018. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: and their article: “Canaccord Upgrades Biogen On Deal Opportunities, Alzheimer’s Pipeline” published on May 31, 2018 as well as‘s news article titled: “Biogen (BIIB) & Samsung Bioepis Co. Report Joint Analysis Results of Anti-TNF Biosimilars BENEPALI (etanercept …” with publication date: June 13, 2018.

Biogen Inc. (NASDAQ:BIIB) Ratings Coverage

Among 24 analysts covering Biogen Inc (NASDAQ:BIIB), 17 have Buy rating, 0 Sell and 7 Hold. Therefore 71% are positive. Biogen Inc had 41 analyst reports since December 20, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, January 25 by Cowen & Co. The company was maintained on Tuesday, April 10 by Bernstein. BMO Capital Markets maintained the shares of BIIB in report on Thursday, January 25 with “Buy” rating. H.C. Wainwright maintained Biogen Inc. (NASDAQ:BIIB) on Wednesday, April 25 with “Buy” rating. The rating was maintained by Oppenheimer with “Buy” on Friday, January 26. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Buy” rating by Credit Suisse on Wednesday, December 20. On Thursday, January 25 the stock rating was maintained by Jefferies with “Hold”. RBC Capital Markets maintained the shares of BIIB in report on Friday, March 2 with “Hold” rating. The stock of Biogen Inc. (NASDAQ:BIIB) has “Overweight” rating given on Wednesday, April 25 by Morgan Stanley. The rating was maintained by Canaccord Genuity on Wednesday, January 24 with “Hold”.

Biogen Inc. (NASDAQ:BIIB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: